European Medicines Agency published a new Guideline on the reporting of Serious Breaches, that will come into effect on January 31, 2022.
Find out:
✔ how to report serious breach
✔ responsibilities of the different parties involved in the notification
✔ examples of serious breaches
✔ template form for reporting
Read more.
Regulation (EU) Nº 536/214 CTR defines ”Serious Breach” as any deviation of the approved protocol version or the clinical trial regulation that is likely to affect the safety, rights of trial participants and/or data reliability and robustness to a significant degree in a clinical trial.
Contact Meditrial for immediate assistance in Europe and in the US.
We will help you to optimize your global product development program!
Table of Contents
Latest Articles
Practical 510(k) vs PMA vs De Novo FDA Pathway Guide
Practical 510(k) vs PMA vs De Novo guidance for choosing an FDA device pathway based on classification, predicates, risk, and evidence needs
Build a Defensible Clinical Evidence Strategy Under EU MDR
Build a defensible clinical evidence strategy under MDR Annex XIV, from the clinical evaluation plan to PMCF and notified body review.
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
This article provides general information and does not constitute regulatory, legal, clinical, or compliance advice. Requirements and appropriate processes may vary by study, product, jurisdiction, and organization. Medigen Suite functionality should be used in accordance with applicable regulations, study documentation, and internal procedures.
